Financial Performance - Total revenue for the three months ended September 30, 2024, was $151.654 million, compared to $153.644 million for the same period in 2023, reflecting a slight decrease[18]. - Gross profit for the nine months ended September 30, 2024, was $303.527 million, up from $293.531 million in the same period of 2023, indicating a year-over-year increase of approximately 3.4%[18]. - The net loss for the three months ended September 30, 2024, was $35.753 million, compared to a net loss of $92.986 million for the same period in 2023, representing a reduction in losses of approximately 61%[18]. - Total revenue decreased by $2.0 million, or 1%, to $151.7 million for the three months ended September 30, 2024, compared to the same period in 2023[103]. - The company incurred net losses of $35.8 million for the three months ended September 30, 2024, compared to $93.0 million for the same period in 2023[101]. Cash and Liquidity - Cash and cash equivalents increased to $398.159 million as of September 30, 2024, from $359.284 million as of December 31, 2023, showing a growth of about 10.8%[15]. - As of September 30, 2024, the company had $398.2 million in cash and cash equivalents, with an accumulated deficit of $1.4 billion since inception[115]. - The net cash provided by operating activities was $13.4 million for the nine months ended September 30, 2024, compared to a net cash used of $41.0 million for the same period in 2023[123][124]. - The company expects to continue incurring operating losses for the foreseeable future but believes existing cash and cash equivalents will meet anticipated cash needs for at least the next 12 months[119]. Expenses and Liabilities - Total current liabilities decreased to $121.235 million as of September 30, 2024, from $127.162 million as of December 31, 2023, indicating a reduction of approximately 4.7%[15]. - The company reported total operating expenses of $147.878 million for the three months ended September 30, 2024, compared to $190.324 million for the same period in 2023, reflecting a decrease of approximately 22.3%[18]. - Research and development expenses for the three months ended September 30, 2024, were $66.174 million, slightly down from $66.507 million in the same period of 2023[18]. - Selling, general and administrative expenses decreased by $0.7 million, or 1%, to $81.7 million for the three months ended September 30, 2024[109]. Assets and Equity - Total assets decreased to $937.794 million as of September 30, 2024, from $965.143 million as of December 31, 2023, representing a decline of approximately 2.8%[15]. - The company’s accumulated deficit increased to $(1,418.019) million as of September 30, 2024, from $(1,284.420) million as of December 31, 2023, indicating a rise in the deficit of approximately 10.4%[15]. - As of September 30, 2023, the total stockholders' equity was $745,216,000, with a net loss of $92,986,000 for the quarter[25]. Revenue Breakdown - Total instruments revenue for the nine months ended September 30, 2024, was $68.4 million, down 19.7% from $85.1 million in the same period of 2023[53]. - Total consumables revenue increased to $359.9 million for the nine months ended September 30, 2024, up 6.1% from $339.2 million in the same period of 2023[53]. - Instruments revenue decreased by $15.9 million, or 45%, to $19.1 million for the three months ended September 30, 2024, primarily due to lower sales of Chromium and Spatial instruments[103]. - Consumables revenue increased by $11.8 million, or 10%, to $126.2 million for the three months ended September 30, 2024, driven by higher Spatial consumables sales[103]. Legal Matters - The Company was awarded over $31 million in damages from NanoString, including approximately $25 million in lost profits and $6 million in royalties[60]. - The jury found that NanoString willfully infringed the asserted patents, and the Company is seeking a permanent injunction and ongoing royalties[60]. - The Company filed a second suit against NanoString alleging infringement of U.S. Patent Nos. 10,227,639 and 11,021,737, with discovery currently in progress[61]. - The Company is involved in multiple legal actions against NanoString, including a counterclaim regarding the Company's Visium products[65]. Stock and Compensation - The weighted-average shares of common stock used in computing net loss per share, basic and diluted, were 120,733,030 for the three months ended September 30, 2024, compared to 117,728,293 for the same period in 2023[18]. - The Company reported stock-based compensation expense of $33.91 million for the three months ended September 30, 2024, compared to $40.24 million for the same period in 2023, reflecting a decrease of approximately 16.5%[86]. - The total number of shares of Class A common stock issued and outstanding as of September 30, 2024, was 106,983,035, with 14,056,833 shares of Class B common stock also outstanding[84]. Future Outlook - The company anticipates capital expenditures of approximately $15 million to $20 million over the next 12 months, focusing on manufacturing and R&D[116]. - The company regularly reviews acquisition and investment opportunities to support long-term growth objectives, which may significantly increase capital needs[118].

PLEASANTON, Calif., Oct. 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Revenue was $151.7 million for the third quarter, in line with the company's preliminary announcement, a 1% decrease over the corresponding period of 2023, primarily driven by lower instrument revenue, offset by stronger contributions from consumables. Began shipping GEM-X Flex, sett ...

PLEASANTON, Calif., Oct. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to democratize access to single cell analysis. The new offerings – GEM-X Flex and GEM-X Universal Multiplex – introduce significant improvements in performance, workflow and cost effectiveness, enabling more researchers to pursue single cell analysis for more applications. These launches are part of the company's str ...

● ● . Torex Gold Reports Q3 2024 Production Results Solidly on track to deliver full-year production guidance following strong third quarter results October 08, 2024 6:00 PM EDT | Source: Torex Gold Resources Inc. Toronto, Ontario--(Newsfile Corp. - October 8, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports Q3 2024 gold production of 119,412 ounces ("oz") and gold sold of 122,130 oz. With year-to-date gold production of 348,728 oz, the Company is on track to achieve annual go ...

● . ● Torex Gold Welcomes the Addition of a New Director Caroline Donally brings extensive mining sector experience in commerce and financial markets September 23, 2024 6:00 PM EDT | Source: Torex Gold Resources Inc. Toronto, Ontario--(Newsfile Corp. - September 23, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to announce the addition of Caroline Donally CA(SA) to its Board of Directors ("the Board") effective October 1, 2024. Rick Howes, Chair of the Board, stated: "Ca ...

In the September 9 cover article of Cancer Cell, researchers integrated 10x single cell and spatial technologies to identify a mechanism of glioblastoma recurrence in mice and develop a promising potential therapeutic approach. PLEASANTON, Calif., Sept. 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its Chromium Single Cell Gene Expression and Xenium In Situ platforms were used in a publication – featured on the cover of Cancer Ce ...

● . ● Torex Gold Integrates EPO Deposit into Morelos Mine Plan Updated mine plan shows a robust long-term production profile that comes with a low risk, capital efficient development plan for EPO September 04, 2024 6:00 PM EDT | Source: Torex Gold Resources Inc. (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - September 4, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports an updated life-of-mine plan for the Morelos Complex whi ...

Toronto, Ontario--(Newsfile Corp. - August 29, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces that on the morning of August 29th, a fatal injury occurred involving a contract worker within the Guajes Tunnel. Jody Kuzenko, President & CEO of Torex, stated: "We are deeply saddened by the death of a 40-year-old male contractor who suffered fatal injuries while working in the Guajes Tunnel and our thoughts are with his family and friends. Our full support is being provided to ...

10x Genomics, Inc. (NASDAQ:TXG) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Cassie Corneau - Director-Investor Relations & Strategic Finance Serge Saxonov - Chief Executive Officer and Co-Founder Justin McAnear - Chief Financial Officer Conference Call Participants Daniel Arias - Stifel Tejas Savant - Morgan Stanley Madeline Mollman - Wolfe Research Marta Zaremba - JPMorgan Kyle Boucher - TD Cowen Kyle Mikson - Canaccord Genuity Michael Ryskin - Bank of America Matthew Sy ...

For the quarter ended June 2024, 10x Genomics (TXG) reported revenue of $153.1 million, up 4.3% over the same period last year. EPS came in at -$0.32, compared to -$0.53 in the year-ago quarter. The reported revenue represents a surprise of +1.46% over the Zacks Consensus Estimate of $150.9 million. With the consensus EPS estimate being -$0.47, the EPS surprise was +31.91%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine ...